alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 810.16 Cease distribution and notification or mandatory recall order status reports. ( a ) The person named in a cease distribution and notification order issued under § 810.10 or a mandatory recall order issued under § 810.13 shall submit periodic status reports to FDA to enable the agency to assess the person's progress in complying with the order. The frequency of such reports and the agency official to whom such reports shall be submitted will be specified in the order.
( b ) Unless otherwise specified in the order, each status report shall contain the following information: ( 1 ) The number and type of health professionals, device user facilities, consignees, or individuals notified about the order and the date and method of notification;
( 2 ) The number and type of health professionals, device user facilities, consignees, or individuals who have responded to the communication and the quantity of the device on hand at these locations at the time they received the communication;
( 3 ) The number and type of health professionals, device user facilities, consignees, or individuals who have not responded to the communication;
( 4 ) The number of devices returned or corrected by each health professional, device user facility, consignee, or individual contacted, and the quantity of products accounted for;
( 5 ) The number and results of effectiveness checks that have been made; and
( 6 ) Estimated timeframes for completion of the requirements of the cease distribution and notification order or mandatory recall order.
( c ) The person named in the cease distribution and notification order or recall order may discontinue the submission of status reports when the agency terminates the order in accordance with § 810.17.
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3450 Ethylene oxide homopolymer and/or karaya denture adhesive. ( a ) *Identification.* Ethylene oxide homopolymer and/or karaya denture adhesive is a device composed of ethylene oxide homopolymer and/or karaya intended to be applied to the base of a denture before the denture is inserted in a patient's mouth to improve denture retention and comfort.
( b ) *Classification.* ( 1 ) Class I if the device is made of wax-impregnated cotton cloth that the patient applies to the base or inner surface of a denture before inserting the denture into the mouth. The device is intended to be discarded following 1 day's use. The class I device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 872.9.
[52 FR 30097, Aug. 12, 1987, as amended at 59 FR 63008, Dec. 7, 1994; 65 FR 2315, Jan. 14, 2000]
**Exhibit32.2**

**CERTIFICATIONPURSUANT TO**

**18 U.S.C.SECTION 1350,**

**ASADOPTED PURSUANT TO**

**SECTION 906OF THE SARBANES-OXLEY ACT OF 2002**

In connection with theQuarterly Report on Form 10-Q of Ebix, Inc. (the “Company”) for the periodended June 30, 2006, as filed with the Securities and Exchange Commission onthe date hereof (the “Report”), I, Richard J. Baum, Chief Financial Officer ofthe Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 ofthe Sarbanes-Oxley Act of 2002, that:

1. The Report fullycomplies with the requirements of section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and

2. The informationcontained in the Report fairly presents, in all material respects, thefinancial condition and results of operations of the Company.

 
| By:                     | /s/ Richard J. Baum |   |
|-------------------------|---------------------|--------|
|                    |                |
| Name:                   | Richard J. Baum     |   |
|                    |                |   |
| Chief Financial Officer |                |
|                    |                |
| August 14, 2006         |                |
|                         |                     |        |  |

 

----

 

----
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 11-6658

UNITED STATES OF AMERICA,

Plaintiff - Appellee,

v.

TANESHA BANNISTER,

Defendant - Appellant.

Appeal from the United States District Court for the District of 

South Carolina, at Columbia. Cameron McGowan Currie, District 

Judge. (3:02-cr-00548-CMC-40; 3:10-cv-70277-CMC)

Submitted: February 17, 2012 Decided: February 23, 2012

Before GREGORY, DUNCAN, and WYNN, Circuit Judges.

Vacated and remanded by unpublished per curiam opinion.

Tanesha Bannister, Appellant Pro Se. Beth Drake, Mark C. Moore, 

Jane Barrett Taylor, Assistant United States Attorneys, 

Columbia, South Carolina for Appellee.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Tanesha Bannister appeals the district court’s order 

denying relief on her 28 U.S.C.A. § 2255 (West Supp. 2011) 

motion, in which she asserted that counsel provided ineffective 

assistance by failing to: (1) communicate a plea offer; (2) 

explain fully how relevant conduct and acceptance of 

responsibility would affect her case; and (3) explain fully the 

application of the 21 U.S.C. § 851 (2006) enhancement and how it 

would affect Bannister’s statutory mandatory minimum sentence.

We previously granted Bannister a certificate of appealability 

on these issues. For the reasons that follow, we vacate and 

remand for further proceedings.

Generally, an evidentiary hearing is required under 

§ 2255 unless it is clear from the pleadings, files, and records 

that a movant is not entitled to relief. United States v. 

Witherspoon, 231 F.3d 923, 925-27 (4th Cir. 2000); Raines v. 

United States, 423 F.2d 526, 529-30 (4th Cir. 1970). Whether an 

evidentiary hearing is necessary is best left to the sound 

discretion of the district court. Raines, 423 F.2d at 530. 

However, when a movant presents a colorable Sixth Amendment 

claim showing disputed facts involving inconsistencies beyond 

the record, a hearing is mandated. See United States v. Magini, 

973 F.2d 261, 264 (4th Cir. 1992); see also Raines, 423 F.2d at 

530 (“There will remain . . . a category of petitions, usually 
3

involving credibility, that will require an evidentiary hearing 

in open court.”).

Because whether counsel’s performance fell below an 

objective standard of reasonableness turns on credibility 

determinations, and since it is not apparent, given the current 

state of the record, that Bannister suffered no prejudice if 

counsel’s performance was deficient, we vacate the district 

court’s order and remand for further proceedings. We dispense 

with oral argument because the facts and legal contentions are 

adequately presented in the materials before the court and 

argument would not aid the decisional process.

VACATED AND REMANDED
# C_2015262EN.01004001.xml

| 10.8.2015 | EN | Official Journal of the European Union | C 262/40 |
| --- | --- | --- | --- |

10.8.2015

EN

Official Journal of the European Union

C 262/40

---

Judgment of the Civil Service Tribunal (3rd Chamber) of 30 June 2015 — Petsch v Commission

(Case F-124/14) (1)

1

((Civil service - Member of the contract staff - Crèche and after-school centre staff - Reform of the Staff Regulations and of the CEOS that entered into force on 1 January 2014 - Regulation No 1023/2013 - Increase in working hours - Additional monthly amount - Article 50 of the Rules of Procedure - Hierarchy of norms - General implementing provisions of Article 110(1) of the Staff Regulations - Article 2 of the annex to the CEOS - Articles 27 and 28 of the Charter of Fundamental Rights of the European Union))

(2015/C 262/54)

Language of the case: French

Parties

Parties

Applicant: Olivier Petsch (Brussels, Belgium) (represented by: J.-N. Louis, R. Metz, D. Verbeke and N. de Montigny, lawyers)

Applicant:

Defendant: European Commission (represented by: C. Berardis-Kayser and G. Berscheid, Agents)

Defendant:

Re:

Re:

Application for annulment of the Commission’s decision not to increase the salary of the applicant, who is a member of the contract staff working at the OIB, in the light of the increase in working hours to 40 hours per week as a consequence of the entry into force of the new Staff Regulations on 1 January 2014.

Operative part of the judgment

Operative part of the judgment

The Tribunal:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Mr Petsch to bear his own costs and to pay the costs incurred by the European Commission. |
| --- | --- |

2.

Orders Mr Petsch to bear his own costs and to pay the costs incurred by the European Commission.

---

(1)  OJ C 7, 12/1/2015, p. 59.

1

---
<PAGE>   1
                                                                    EXHIBIT 23.2

               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS

We consent to the reference to our firm under the caption "Experts" in the
Registration Statement (Form S-3) and related Prospectus of Corixa Corporation
for the registration of 170,224 shares of its common stock and to the
incorporation by reference therein of: (i) our report dated February 22, 1999
with respect to the financial statements of Anergen, Inc. included in Current
Report on Form 8-K of Corixa Corporation dated August 9, 1999; and (ii) our
report dated February 6, 1998 except for the second paragraph of Note 1, as to
which the date is December 21, 1998 with respect to the financial statements of
Anergen, Inc., included in Current Report on Form 8-K of Corixa Corporation
dated February 12, 1999, filed with the Securities and Exchange Commission.

                                                   Ernst & Young, LLP

Seattle, Washington
August 9, 1999



                                      II-8
§ 522.88 Amoxicillin. ( a ) *Specifications.* ( 1 ) Each vial contains 3 grams (g) of amoxicillin trihydrate. Each milliliter of constituted suspension contains 100 or 250 milligrams (mg) amoxicillin trihydrate for use as in paragraph (d)(1) of this section.
( 2 ) Each vial contains 25 g of amoxicillin trihydrate. Each milliliter of constituted suspension contains 250 mg amoxicillin trihydrate for use as in paragraph (d)(2) of this section.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Related tolerance.* See § 556.38 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Dogs and cats* — ( i ) *Amount.* Administer 5 mg per pound of body weight daily for up to 5 days by intramuscular or subcutaneous injection.
( ii ) *Indications for use* — ( A ) *Dogs.* For treatment of infections caused by susceptible strains of organisms as follows: Respiratory infections (tonsillitis, tracheobronchitis) due to *Staphylococcus aureus, Streptococcus* spp., *Escherichia coli,* and *Proteus mirabilis;* genitourinary infections (cystitis) due to *S. aureus, Streptococcus* spp., *E. coli,* and *P. mirabilis;* gastrointestinal infections (bacterial gastroenteritis) due to *S. aureus, Streptococcus* spp., *E. coli,* and *P. mirabilis;* bacterial dermatitis due to *S. aureus, Streptococcus* spp., and *P. mirabilis;* soft tissue infections (abscesses, lacerations, and wounds), due to *S. aureus, Streptococcus* spp., *E. coli,* and *P. mirabilis.*
( B ) *Cats.* For treatment of infections caused by susceptible strains of organisms as follows: Upper respiratory infections due to *S. aureus, Staphylococcus* spp., *Streptococcus* spp., *Haemophilus* spp., *E. coli, Pasteurella* spp., and *P. mirabilis;* genitourinary infections (cystitis) due to *S. aureus, Streptococcus* spp., *E. coli, P. mirabilis,* and *Corynebacterium* spp.; gastrointestinal infections due to *E. coli, Proteus* spp., *Staphylococcus* spp., and *Streptococcus* spp.; skin and soft tissue infections (abscesses, lacerations, and wounds) due to *S. aureus, Staphylococcus* spp., *Streptococcus* spp., *E. coli,* and *Pasteurella multocida.*
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Cattle* — ( i ) *Amount.* Administer 3 to 5 mg per pound of body weight daily for up to 5 days by intramuscular or subcutaneous injection.
( ii ) *Indications for use.* For treatment of diseases due to amoxicillin-susceptible organisms as follows: Respiratory tract infections (shipping fever, pneumonia) due to *P. multocida,* *P. hemolytica, Haemophilus* spp., *Staphylococcus* spp., and *Streptococcus* spp. and acute necrotic pododermatitis (foot rot) due to *Fusobacterium necrophorum.*
( iii ) *Limitations.* Treated animals must not be slaughtered for food during treatment and for 25 days after the last treatment. Milk from treated cows must not be used for human consumption during treatment or for 96 hours (8 milkings) after last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16183, Mar. 25, 2014]
* Pursuant to 5TH CIR. R. 47.5, the court has determined that

this opinion should not be published and is not precedent except

under the limited circumstances set forth in 5TH CIR. R. 47.5.4.

United States Court of Appeals

Fifth Circuit

FILED

March 1, 2006

Charles R. Fulbruge III

Clerk

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

 

No. 05-50318

Summary Calendar

 

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

JESSICA GARCIA-AGUIRRE,

Defendant-Appellant.

--------------------

Appeal from the United States District Court

for the Western District of Texas

(2:04-CR-639-ALL)

--------------------

Before KING, WIENER, and DeMOSS, Circuit Judges. 

PER CURIAM:*

Defendant-Appellant Jessica Garcia-Aguirre (Garcia) appeals

her guilty-plea conviction and sentence for being unlawfully

present in the United States following deportation. Garcia asserts

that the district court erred in enhancing her sentence under

U.S.S.G. § 2L1.2(b)(1)(A)(ii) based on a Texas prior conviction for

aggravated robbery. As Garcia did not raise this issue in the

district court, review is limited to plain error. United States v.

Calverley, 37 F.3d 160, 162-64 (5th Cir. 1994) (en banc). 
2

Under § 2L1.2(b)(1)(A)(ii), a defendant’s base offense level

is increased by 16 levels if he was previously deported after being

convicted of a crime of violence. Robbery is an offense expressly

listed as a crime of violence in the application notes to 

§ 2L1.2. § 2L1.2, comment. (n.1(B)(iii)). A prior conviction will

qualify as a crime of violence if it is specifically identified in

the commentary definition, regardless whether it has the use of

force as an element. United States v. Izaguirre-Flores, 405 F.3d

270, 273-75 (5th Cir.), cert. denied, 126 S. Ct. 253 (2005). We

use a “common sense approach” to determine whether a defendant’s

offense qualifies as an offense identified in § 2L1.2, comment.

(n.1(B)(iii)). Id.

Garcia has not shown that the district court’s increase in her

offense level pursuant to § 2L1.2 based on her prior Texas

conviction for aggravated robbery was a “clear or obvious” error.

See Izaguirre-Flores, 405 F.3d at 273-75; see also United States v.

Calderon-Pena, 383 F.3d 254, 261 n.11 (5th Cir. 2004) (en banc).

Garcia also contends that 8 U.S.C. § 1326(b) is

unconstitutional. She acknowledges that this argument is

foreclosed by Almendarez-Torres, 523 U.S. 224, 235 (1998), but

raises it to preserve it for further review. We have “repeatedly

rejected arguments like the one made by [Garcia] and . . . held

that Almendarez-Torres remains binding despite Apprendi[ v. New

Jersey, 530 U.S. 466 (2000).]” United States v. Garza-Lopez, 410
3

F.3d 268, 276 (5th Cir.), cert. denied, 126 S. Ct. 298 (2005).

Garcia’s guilty-plea conviction and the sentence imposed are 

AFFIRMED.
Guía para su salud

1 COMIENCE 

AQUÍ 

Dele prioridad a 

su salud

• Mantener su salud es importante para usted

y para su familia.

• Lleve un estilo de vida saludable en su casa, 

en su trabajo, y en su comunidad.

• Hágase las pruebas médicas que le

recomienden y maneje sus enfermedades

crónicas.

• Guarde toda su información médica en el

mismo lugar.

2

Entienda su cobertura 

de salud 

• Comuníquese con su plan de seguro o con

el programa estatal de Medicaid o CHIP para

que vea qué servicios están cubiertos.

• Familiarícese con sus costos (primas, 

copagos, deducibles, coseguro).

• Entienda la diferencia entre los proveedores

dentro de la red y fuera de la red.

3

Entienda dónde debe ir si 

necesita atención médica

• Vaya a la sala de emergencias si tiene una

situación que ponga en peligro su vida.

• En caso de que no sea una emergencia, es

preferible que vaya al médico primario.

• Entienda la diferencia entre cuidados primarios y

cuidados de emergencia.

4

Encuentre un 

proveedor

• Pregúntele a sus amistades o

investigue por Internet.

• Revise la lista de proveedores de su

plan.

• Si le asignan un proveedor, 

comuníquese con su plan si quiere

cambiarlo.

• Si está inscrito en Medicaid o en

CHIP, comuníquese con el programa

estatal de Medicaid o CHIP para que

lo ayuden.

5 Haga una cita

• Dígales si es un paciente nuevo o si ya ha estado

antes ahí.

• Dé el nombre de su plan de seguro y pregunte si

aceptan su seguro.

• Dígales el nombre del proveedor que usted

quiere ver y por qué quiere una cita.

• Pregunte si están disponibles en los días y

horarios más convenientes para usted.

6 Esté preparado para la 

consulta

• Lleve su tarjeta de seguro.

• Investigue la historia médica de su familia y haga

una lista de los medicamentos que esté tomando.

• Lleve una lista de preguntas y cosas de las que

quiera hablar, y tome notas durante la consulta.

• Lleve a alguien para que lo acompañe si necesita

ayuda.

No

Si quiere cambiar 

de proveedor, 

regrese al Paso 4. 7

Sí

Decida si el proveedor 

es el adecuado para 

usted 

• ¿Se sintió cómodo con el proveedor que

lo atendió?

• ¿Pudo comunicarse y entender a su

proveedor?

• ¿Le parece que usted y su proveedor

pueden tomar buenas decisiones juntos?

• Recuerde: ¡Cambiar de proveedor no es

ningún problema!

8

Próximos pasos después de su cita

• Siga las instrucciones de su proveedor.

• Ocúpese de que le surtan los medicamentos por receta que le hayan

dado, y tómelos según le hayan indicado.

• Haga una cita para la siguiente visita si es necessario.

• Revise la explicación de beneficios y pague sus cuentas médicas.

• Comuníquese con su proveedor, plan de salud, o la agencia estatal de

Medicaid o CHIP si tiene alguna pregunta.

Para más información, visite go.cms.gov/c2c CMS Producto No. 11822-S

Revisado en septiembre de 2016
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1545 Parathyroid hormone test system. ( a ) *Identification.* A parathyroid hormone test system is a device intended to measure the levels of parathyroid hormone in serum and plasma. Measurements of parathyroid hormone levels are used in the differential diagnosis of hypercalcemia (abnormally high levels of calcium in the blood) and hypocalcemia (abnormally low levels of calcium in the blood) resulting from disorders of calcium metabolism.
( b ) *Classification.* Class II.
<TABLE> <S> <C>

<ARTICLE>                     5
<LEGEND>
THE SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED FINANCIAL STATEMENTS OF LADISH CO., INC. AS OF AND FOR THE
THREE MONTHS ENDED MARCH 31, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER>                                   1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-START>                                 JAN-01-2000
<PERIOD-END>                                   MAR-31-2000
<CASH>                                         7,111
<SECURITIES>                                   0
<RECEIVABLES>                                  33,587
<ALLOWANCES>                                   340
<INVENTORY>                                    51,274
<CURRENT-ASSETS>                               91,993
<PP&E>                                         158,664
<DEPRECIATION>                                 (66,187)
<TOTAL-ASSETS>                                 202,500
<CURRENT-LIABILITIES>                          70,403
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       143
<OTHER-SE>                                     78,370
<TOTAL-LIABILITY-AND-EQUITY>                   202,500
<SALES>                                        54,852
<TOTAL-REVENUES>                               54,852
<CGS>                                          46,249
<TOTAL-COSTS>                                  2,228
<OTHER-EXPENSES>                               36
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             (444)
<INCOME-PRETAX>                                5,967
<INCOME-TAX>                                   1,074
<INCOME-CONTINUING>                            4,893
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   4,893
<EPS-BASIC>                                  0.36
<EPS-DILUTED>                                  0.35


</TABLE>
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.7660 Leukocyte alkaline phosphatase test. ( a ) *Identification.* A leukocyte alkaline phosphatase test is a device used to identify the enzyme leukocyte alkaline phosphatase in neutrophilic granulocytes (granular leukocytes stainable by neutral dyes). The cytochemical identification of alkaline phosphatase depends on the formation of blue granules in cells containing alkaline phosphatase. The results of this test are used to differentiate chronic granulocytic leukemia (a malignant disease characterized by excessive overgrowth of granulocytes in the bone marrow) and reactions that resemble true leukemia, such as those occuring in severe infections and polycythemia (increased total red cell mass).
( b ) *Classification.* Class I (general controls). This device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
[45 FR 60623, Sept. 12, 1980, as amended at 59 FR 63007, Dec. 7, 1994; 66 FR 38790, July 25, 2001]